Axa

Axa’s Crescent Biopharma CBIO Stock Holding History

Axa’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,877	Closed	-$4.76M	–	1093
2024 Q1	$4.76M	Buy	15,877 +4	+0%	+$1.2K	0.01%	566
2023 Q4	$3.75M	Sell	15,873 -384	-2%	-$59.7K	0.01%	611
2023 Q3	$2.44M	Sell	16,257 -58	-0.4%	-$9.15K	0.01%	673
2023 Q2	$2.84M	Buy	16,315 +224	+1%	+$37.6K	0.01%	663
2023 Q1	$2.03M	Buy	+16,091	New	+$3.62M	0.01%	761
2020 Q2	–	Sell	-306	Closed	-$70K	–	1256
2020 Q1	$70K	Sell	306 -9,146	-97%	-$3.5M	﹤0.01%	1150
2019 Q4	$5M	Buy	9,452 +323	+4%	+$175K	0.02%	620
2019 Q3	$3.93M	Sell	9,129 -177	-2%	-$114K	0.02%	720
2019 Q2	$11.1M	Buy	9,306 +55	+0.6%	+$65.8K	0.04%	447
2019 Q1	$11.5M	Buy	9,251 +159	+2%	+$182K	0.05%	423
2018 Q4	$8.61M	Buy	9,092 +1,834	+25%	+$2.21M	0.04%	462
2018 Q3	$10.5M	Buy	7,258 +1,129	+18%	+$1.71M	0.04%	472
2018 Q2	$9.89M	Buy	6,129 +1,043	+21%	+$1.79M	0.04%	455
2018 Q1	$8.26M	Sell	5,086 -24	-0.5%	-$49.9K	0.03%	512
2017 Q4	$8.58M	Buy	+5,110	New	+$6.76M	0.03%	516

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return